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1. Introduction  
1.1 Diabetes and mental health 
Diabetes mellitus is a severe chronic life-long disease, which is diagnosed in about 6% of the 
population. In many aspects it is considered a psycho-somatic disease. Some mental 
disorders, especially depression, are more common in diabetic patients compared to the rest 
of the population. Diabetes mellitus affects psyche of the patients, but at the same time 
mental state of the patients influences the course of diabetes. The causal links are different 
depending on the type of diabetes and mental disorder. Nonetheless, the association is 
observed on a level of emotions and mental processes, but also in biochemical and hormonal 
aspects. In this article we will focus only on diabetes mellitus type 1.  
From the moment of diagnosis, diabetes introduces substantial changes in life of a patient. 
His life-style should be adjusted to them in order to make the course of the disease as 
favorable as possible. This disease demands maintaining a regular daily regime regarding 
food and physical activity. The patients must watch their body-weight and measure blood 
glucose several times a day. Blood pressure and blood lipid level belong to strictly 
monitored parameters in diabetic patients. Their increase in combination with diabetes 
significantly influences the cardio-vascular risk of the patients. 
Diabetes mellitus type 1 is caused by a selective destruction of beta cells in islets of 
Langerhans by an immunologic process in genetically predisposed individuals. It is specific 
by onset in younger age and dependence on insulin since the beginning of the treatment. 
[Bartoš, 2003] 
1.2 Diabetes and depression  
The relationship between depression and diabetes is bilateral. Recently, they have been 
identified as reciprocally interacting risk factors – the presence of diabetes deteriorates the 
prognosis of depression, while the presence of depression worsens the prognosis of 
diabetes. [Höschl, 2005] 
www.intechopen.com
 
Effects of Antidepressants 164 
Prevalence of a more or less severe depression is approximately double in patients with 
diabetes compared to a general population. On average, it is present in 14% (9 to 27%) of 
diabetics in the Czech Republic. [Češková, 2004]  Depressive reactions in diabetic patients 
show a higher recurrence tendency in comparison with general population. Depression is 
more frequent in women.  Depression usually follows the diagnosis of the disease in this 
type of diabetes. Diabetes as a primary disease is typically superimposed by depression as a 
reactive state. Depression is usually a result of exposure to psycho-social factors that are 
related to hardship caused by chronic disease. It is necessary to look for associations at the 
level of emotions and mental processes. For many patients it is difficult to maintain a 
regular life-rhythm. Their roles in social environment may change as well. Moreover, the 
patients often loose energy more rapidly. It often takes years until a man accepts and fixates 
a change in his lifestyle to which he is accustomed. It is even possible that the internal and 
mental manifestations of diabetes share a common origin. It can be explained through a 
correlation of insulin resistance and changes in central serotonin system. [Horáček, 1997] 
Hyperglycemia, hyperinsulinemia and impaired peripheral insulin receptor sensitivity is 
often found in patients with depression. Decreased insulin sensitivity is associated with 
lower serotoninergic activity. [Höschl, 2004] 
Many chronic autoimmune diseases, including the insulin-dependent diabetes mellitus, are 
accompanied with symptoms of depression. However, a reversed association is also 
possible. Autoimmune diseases are generally more common in depressed rather than non-
depressed population. One of the predisposing factors of onset of an autoimmune disorder 
is a serious life event that can alter the cell-mediated as well as the humoral immunity.  
Furthermore, symptoms of depression often overlap with poorly controlled diabetes 
symptoms. It is necessary to look for the etiologic connections here as well. The cardinal 
symptoms include low stamina, fatigue hypomimia, change in body weight, polymorphic 
somatic complaints, impaired concentration, etc. Even an increase in blood glucose itself can 
lead to a significant change in mood, including sadness and increased fatigue [Polonsky, 1999] 
Several studies concerning comorbidity of type 1 diabetes and depression identified risk 
factors of depression development; chronic somatic comorbidity and polypharmacy, female 
gender, higher age, solitary life, lower than secondary education, lower financial status, 
cigarette smoking, obesity, diabetes complications and a higher glycosylated hemoglobin 
[Engum, 2005; Bell, 2005; Hermanns, 2005; Katon, 2004]  
Studies dealing with consequences of comorbidity of diabetes and depression claim that 
depression leads to a decrease in metabolic control of diabetes, reduction of treatment 
response and diet measures effect, deterioration of the quality of life and increase in 
healthcare costs. [Lustman, 2005] In addition, depressive symptoms have an impact on later 
somatic problems associated with poor glycemic control, because they affect the patients' 
ability to care for themselves and follow diet. [McKellar, 2004] Blood glucose regulation is 
also significantly impaired in depressed patients, compared to individuals without 
depression. Insufficient regulation of blood glucose can adversely influence patient's state of 
mind and his response to antidepressant drugs. The incidence of microvascular 
complications (especially retinopathy, but also neuropathy, nephropathy, and sexual 
dysfunction) and macrovascular complications is also higher in diabetic patients with 
depression. This is related to poor metabolic control in depressed compared to the non-
depressed diabetic patients.  
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Furthermore, it was proven that a depression increases mortality in patients with diabetes; the 
probability of death within 10 years is significantly increased in these patients. [Zhang, 2005] 
1.3 Antidepressant drug treatment in type 1 diabetic patients 
Psychiatric treatment of diabetic patients is focused on treatment of their mental disorder 
with respect to diabetes, and on improvement in quality of life with disease. Furthermore, 
the psychiatrist may try to positively influence the glycemic control. The literature is 
unequivocal regarding the effect of a psychiatric treatment on glycemic control. Some 
studies declare its benefit in glycemic control improvement, however, most of them do not 
confirm it. An important randomized clinical trial demonstrated that extended treatment of 
patients with diabetes mellitus and severe depression or dysthymia lead an improvement in 
mental state. However, the improvement in depression itself from the antidepressant 
therapy did not lead to any improvement in blood glucose, or any significant change in 
glycemic hemoglobin level. [Katon, 2004 b] 
Antidepressant drugs are most commonly administered psychiatric medication. They are 
used for therapy of mental disorders, as well as e.g. treatment of painful diabetic 
neuropathy.   
Several research efforts regarding the effect of antidepressant drug treatment on glycemic 
control in depressed diabetics were conducted. According to a study by Lustman et al. the 
glycosylated hemoglobin decreases during the open treatment phase and remains 
significantly reduced during depression-free maintenance, regardless of the fact whether the 
patients are treated by an antidepressant, sertraline in this case, or by placebo. [Lustman, 
2006] Another study with sertraline demonstrated that a specific minor population of 
diabetics with low financial income showed a significant reduction in glycosylated 
hemoglobin after the initiation of pharmacologic treatment of depression in comparison 
with placebo. [Echeverry, 2009] Elder diabetic patients with depression, presented in 
another work, who went through the antidepressant treatment were less likely to die within 
5 years compared to depressed diabetics without the treatment.[Bogner, 2007] 
The antidepressant drugs are also used as co-analgesics (adjuvant analgesics) in the 
treatment of painful peripheral diabetic polyneuropathy. They are even more effective than 
common analgesics. The effect on pain is direct, through the intervention in 
neurotransmission (serotonin and noradrenaline) and indirect (antalgic) acting through a 
change in attention distribution, lowering the pain threshold, reducing emotional 
accompaniment and reducing stress response brought about by the pain. The analgesic 
effect of antidepressants arises more rapidly than the antidepressant effect, already at lower 
doses and is independent of the presence of depression in the patient. The antidepressant 
drugs are the treatment of the first choice in a constant burning pain. [Doležal, 2006] 
When treating a diabetic patient with antidepressants, it is important to notice how the 
medication influences the blood glucose, body weight, blood pressure, and renal functions. 
If it influences glycemia, it is necessary to advise the patient ahead that a dosage change in 
insulin or oral antidiabetic drugs may be necessary. The body weight increases the most 
after tricyclic antidepressants and mirtazapine use and the least after SSRI, MAOI a 
trazodone. An increase in blood glucose was described in association with TCA, a decrease 
after SSRI and MAOI. 
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1.4 Use of individual antidepressant drug groups 
The longest used tricyclic antidepressants (TCA) decrease insulin secretion, increase blood 
glucose, appetite for sweets and body weight. Amitriptyline from this group is used even 
for diabetic painful peripheral neuropathy treatment.  
Selective serotonin reuptake inhibitors (SSRI) decrease blood glucose (even 30% decrease in 
fasting glycemia has been described), temporarily reduce body weight (most often described 
in fluoxetine), however, they increase body weight in long-term. They reduce 
cholesterolemia and serum triglycerides. Citalopram and sertraline have a low potential in 
creating drug interactions. CYP 3A4 inhibition by fluvoxamine may disrupt metabolism of 
oral antidiabetic drugs. CYP 2C9 inhibition by fluoxetine, fluvoxamine or sertraline can 
interfere with the metabolism of sulfonylurea and tolbutamide. [Češková, 2004] In 
combination they can lead to hypoglycemic states, as these antidepressants cause an 
increase in the level of the abovementioned antidiabetic drugs.  
Trazodone is a postsynaptic 5HT2 blocker and a weak serotonin reuptake inhibitor (SARI). 
It has considerable hypnotic effects and does not have a negative influence on metabolism.  
[Svačina, 2004] 
Moclobemide from the Monoamine Oxydase Inhibitors (MAOI) group reduces blood 
glucose and can thus lead to hypoglycemic states. On the other hand, it usually does not 
increase body weight. 
Norepinephrine dopamine reuptake inhibitor (NDRI) bupropion is neutral regarding the 
influence on body weight. Higher doses in combination with insulin lower seizure threshold 
(the risk of epilepsy is increased especially in patients with concomitant mental anorexia). 
This effect is eliminated in the SR form. Bupropion attenuates sexual dysfunction and 
facilitates smoking cessation. Both effects are of great importance in diabetic patients, as 
they suffer from diabetes-associated sexual dysfunction and have elevated cardiovascular 
risk from smoking.    
Noradrenergic and specific serotonergic antagonist (NaSSA) mirtazapine induces sedation 
and can therefore be used in insomnia. However, it increases appetite and body weight, 
which is undesirable in diabetic patients. Furthermore, it can lead to an increase in 
glycosylated hemoglobin and thus deteriorate a long-term glycemic control. [Šabaková, 
2008] 
From the group of serotonin norepinephrine reuptake inhibitors (SNRI), it is necessary to 
mention venlafaxine and duloxetine. Venlafaxine does not increase body weight. A small, 
but statistically significant increase in fasting glycemia was found when using duloxetine in 
comparison with placebo. [Fava, 2004] Venlafaxine [Kunz, 2000; Rowbotham, 2004] as well 
as duloxetine [Goldstein, 2005; Raskin, 2005] have a well-established effect on chronic 
neuropathic pain.  
St John's wort extract (hypericin) does not increase body weight, however, there is a high 
risk of drug interactions. 
Summary of antidepressant drug use is presented in table 1. 
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Antidepressant group 
(representative) 
Important effects in diabetic 
patients 
Use in neuropathy 
treatment 
TCA (amitriptyline) 
Increase glycemia, increase 
body weight 
+ 
SSRI (citalopram, sertraline) 




Reduce glycemia, do not 
increase body weight 
- 
NDRI (bupropion) Do not increase body weight - 
NaSSA (mirtazapine) 
Increase body weight and 
glycosylated hemoglobin 
- 
SNRI (venlafaxine, duloxetine) 
Do not increase body weight, 
duloxetine increases fasting 
glycemia 
+ 
St. John's wort (hypericin) 
Do not increase body weight, 
risk of drug interactions 
- 
Table 1. Antidepressant drug use in diabetic patients 
2. Case studies  
The following case studies are pointing out patients with depression anxiety problems and 
diabetes mellitus type 1, where the antidepressant treatment was successful regarding 
mental state improvement and positive effect on glycemic control.  
We chose to convey the information in form of case reports, because in spite of the fact that 
numerous studies concerning the influence of antidepressant drug treatment on glycemic 
control in diabetes mellitus have been performed, their conclusions differ or are even 
contradictory. This work should point out the diabetics, in whom the antidepressant 
treatment led to an improvement in glycemic control. They are the evidence that the use of 
specifically selected antidepressant drugs is suitable in diabetic patients, owing to the fact 
that any, even temporary improvement in glycemic control is desirable.  
This article is focused on type 1 diabetic patients, as this type of diabetes is less represented 
in studies that deal with diabetes comorbidity, mental problems and their treatment using 
psychiatric medication.  
Patients with e.g. a change in insulin dose or insulin delivery mode were excluded in order 
to clearly demonstrate the effect of the antidepressant drugs. Only the patients who did not 
undergo any significant change in chronic internal medication, which could have a 
significant effect on the change in glycemic control, are presented in the case reports.  
Mental state of the patients was evaluated by a clinical psychiatric examination and on the 
basis of patients' complaints regarding their subjective problems. The general mental state of 
the patients was evaluated using Clinical Global Impression - Severity (CGI-S), which is 
widely used for global clinical impression assessment of psychiatric patients. The scale 
ranges from 1 to 7 points, where 1 means "no apparent signs of illness" and 7 denotes 
extremely expressed symptoms. Data is acquired from information regarding behavior of 
the patient and a change in his state in the course of the treatment. [Busner, 2009] 
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Long-term glycemic control was evaluated according to the glycosylated hemoglobin level. 
Its values are presented according to DCCT/NGSP calibration. Other somatic and metabolic 
parameters that are regularly monitored in diabetic patients were also recorded, specifically 
body weight, blood pressure and blood level of triglycerides and cholesterol. Monitoring of 
these parameters served for assessment of a potential effect of administered psychiatric 
drugs on metabolic functions in diabetic patients. 
Patient No. 1 was born in 1963. She has been treated with type 1 diabetes since 1987, i.e. when 
she was 24 years old. She has been treated by intensified insulin regimen since 2008. From 
chronic diabetic complications, she suffers from lower-extremity polyneuropathy and 
cardiovascular autonomous neuropathy. Furthermore, she is treated for arterial hypertension, 
iron deficiency anemia, and dyslipidemia. She is obese. In 2009, she went through a transient 
ischemic attack and suffers from migraine ever since. Her family history is positive regarding 
diabetes in grandfather from mother's side, negative regarding mental disorders. The patient 
works as a staff at a gas station. She is married, has 5 children, her marriage is conflicting. 
She was first referred to a psychiatrist in March 2010, i.e. in her 48 years, because of long-
term poor glycemic control and putative influence of mental and family problems.  
Already at the first contact, the patient reported long-term deteriorated glycemic control and 
put it herself in connection with family problems that distressed her. She felt weak for about 
half a year, nothing amused her, she did not care about anything, nothing could make her 
happy, and she resigned to important things. She described her problems in relationship 
with her partner and acknowledged that she was overburdened by the care of her 
household with five children. She did not mind working, she was engaged in charity 
activities. CGI-S – 4 points. 
In contact she seemed depressed, in tension, with paradoxically psychomotor agitation and 
inadequate and excess emotionality. She answered in extensive sentences and often could 
not adhere to her topic. The accentuation of personal histrionic features was apparent. 
A diagnosis of a moderately severe depressive phase based on histrionic features of 
personality was set and a treatment with antidepressant drug with active substance 
sertraline was initiated. The daily dose of 100 mg was reached through a gradual titration 50 
mg daily for the first week. 
Mental state of the patient has completely restituted within the first month of antidepressant 
use. Mood normalized, the patient started enjoying things she liked or liked doing, tension 
and irritation disappeared, the psychomotor pace stabilized. Excessive emotionality within 
personality prevailed, but the patient was satisfied with her state. CGI-S – 2 points. 
Although the situation in her family did not improve, she had more strength to face the 
problems. Her mental state is stabilized to date. She attends our psychiatric out-patient 
department every three months. The antidepressant dose was continued owing to persisting 
unsatisfactory situation in her family.  
Her glycemic control improved significantly at the beginning of the psychiatric treatment. 
Glycosylated hemoglobin decreased from 9.4% at the first contact in March 2010 to 8.0% in 
May. It rose to 8.8% in October, 9.2% in January 2011, and returned to 9.4% in May 2011.  
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Psychological status (treatment) time HbA1c 
moderately severe depressive phase (sertraline 
treatment initiation) 
03 / 2010 9.5 
without depression 04 / 2010  
full compensation 05 / 2010 8.1 
continuation of medication 10 / 2010 8.8 
 01 / 2011 9.3 
continuation of cooperation 05 / 2011 9.5 
Table 2. Timeline of mental state and glycosylated hemoglobin level development - patient No.1 
Body weight of the patient was 111kg at the beginning of the treatment (March 2011), it was 
115kg in the end (May 2011). There was thus a small increase in the course of the treatment 
observed. 
Blood pressure of the patient was stable, 125/70 torr since the beginning of the treatment. It 
was not affected by the antidepressant drug treatment. 
Her serum triglyceride level was 3.66 mmol/l at the beginning of the treatment, it was 2.33 
mmol/l after 6 months, it increased to 3.10 mmol/l 10 months after the beginning of the 
treatment and 5.98 mmol/l in the end of the treatment. The psychiatric treatment thus led to 
a gradual increase in serum triglyceride level. Serum cholesterol level was 5.25 mmol/l at 
the beginning of the treatment  and remained unchanged in the course of the treatment. 
The depressive disorder completely normalized owing to the antidepressant medication. 
Her mental state is now long-term stabilized due to the treatment. The long-term glycemic 
control of the diabetes rapidly improved at the beginning of the psychiatric treatment, 
however, it returned to its original value within 15 months. 
The case of this woman confirms that depressive disorder improvement and stress 
reduction lead to a decrease in glycemia. The antidepressant drug itself could have played a 
role in glycemic control improvement. Active substances from the SSRI group may cause a 
decrease in glycemia, which in turn can lead to a decrease in glycosylated hemoglobin level. 
The effect is probably only temporary. The initial effect of a new attitude towards her 
therapy, i.e. psychiatric treatment initiation, can partly participate in the glycemic control 
improvement.   
Patient No. 2 was born in 1964. She was diagnosed with diabetes mellitus type 1 in 1991, 
i.e. when she was 27 years old. She has been treated by intensified insulin regimen since 
2003. She gradually developed chronic complications of diabetes; diabetic peripheral 
polyneuropathy, non-proliferative diabetic retinopathy, moreover, she was treated with a 
diabetic foot syndrome of neuropathic etiology in past. Furthermore, she is treated with 
hyperfunction of the thyroid gland and arterial hypertension since 1996. She also suffers 
from cervical pain. She underwent appendectomy in 1998. Her family history regarding 
diabetes is positive; her grandmother had a diabetes type 2. Her family history is positive 
regarding mental disorders; her brother and father are alcoholics. The patient is married 
and has two adolescent children. She is a certified shop assistant. She had worked as a 
ceramic printer, but she retired to a disability pension a few months before the psychiatric 
treatment commencement, which relieved her from overloading. She is only partly 
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content with the relationships in her family; she feels that her children do not need her 
anymore and her husband devotes too little time to her. She is thus forced to look for her 
own activities. 
She was referred to a psychiatric care in May 2005, i.e. when she was 41 years old, by her 
diabetologist for symptoms of anxiety and depression. At the time of referral, she was 
already taking an antidepressant for about half a year.  She was given 100mg of sertraline by 
her diabetologist with an insufficient effect leading to an impaired sexual appetite as an 
adverse effect. 
At the first visit at the psychiatrist she complained about a long-term perceived inner 
tension, tearfulness, inhibitedness, easy fatigability, feelings of uselessness, general 
dissatisfaction and sexual problems. Moreover, she regarded her diabetes disease as a heavy 
burden that restricted her at all times and destined her to be monitored by others. She was 
aware of dependence on her husband and children, which further exhausted her. Her mood 
was already more positive since she was taking sertraline.  
In contact she seemed subdepressed, inhibited, tired, with a psychomotor retardation, 
slightly blunted affect, hypobulia and apathy. She answered after increased pauses before 
answering. CGI-S – 4 points. 
Diagnosis of a moderately severe depressive phase and accented dependant personality 
features was made. Her medication was changed to bupropione 15mg daily because of 
dominant inhibitedness and fatigability. At the following visit after a month, the patient 
reported an improvement in sexual appetite, but increased nervousness, tension and 
anxiety, she was tearful and felt that she could not deal with daily life. The antidepressant 
was therefore changed to trazodon titrated gradually up to a dose of 150 mg a day. CGI-S – 
4 points. The patient came for the next visit after 3 months, i.e. in September 2005. She 
reported a relief from depression, anxiety and fatigue. She also talked about an ambivalent 
attitude of her husband to the treatment, who perceived his wife as unnaturally sedated. 
The problems with sexual appetence and tearfulness prevailed. CGI-S – 4 points. Trazodon 
daily dose was increased to 200mg. 
The patient reported a decline of all mental problems at a visit next month (October 2005), 
her mental state was stabilized. CGI-S – 2 points. The following month (November 2005), 
she complained of enhanced anxiety, nervousness and distractedness. She had no 
depressive moods, sleeping disorders or problems in sexual field. She complained of 
diarrhea and abdominal cramps of unknown etiology for several months and thus a lower 
appetite and a significant body weight loss. CGI-S – 3 points. The previous daily dose of 
trazodon 150mg was resumed and the treatment was augmented by sulpiride at a daily 
dose of 50mg (since November 2005). The digestive problems gradually disappeared, 
however, increased fatigability prevailed. CGI-S – 2 points. Trazodon was gradually 
withdrawn and only sulpirid treatment continued (since April 2005). The patient 
consequently reported a complete amelioration of mental problems and disappearance of 
digestive problems and was satisfied with her medication. She insisted on its continuation in 
spite of the fact that it caused a mild menstrual disorder. Stability of her state lasted until a 
visit in October 2007 despite the fact that her 18 year-old daughter delivered her first 
granddaughter, which was a significant strain.   
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At her following visit in December 2007 she complained about depressive moods and 
worsening of feelings of refusal from her daughter and husband that were producing fear 
from future and loneliness. CGI-S – 3 points. Sertraline treatment at a dose of 50mg per day 
was initiated, owing to objective deterioration of the depressive disorder and a concern 
about further mood depression. Consequently, the mental state improved significantly 
again, the patient even started to look for own activities more and was generally satisfied 
with her life. CGI-S – 1 point. This lasted from January until September 2008. Meanwhile, 
the patient tried to discontinue sertraline, but she felt more even-tempered while using it 
and therefore decided to use it chronically.   
In September 2008, the patient came for a visit complaining about subjectively deteriorated 
short-term memory and concentration. CGI-S – 2 points. She was educated about cognitive 
training and was given a preparation with an extract from Ginkgo biloba at a daily dose 
gradually increased to 160mg. The dose was reduced to 80mg after approximately 6 months 
and continued until October 2010. All this time she felt psychically stabilized, even though 
she developed some serious somatic problems associated with diabetes - Charcot 
osteopathy. 
 
Psychological status (treatment) time HbA1c 
moderately severe depressive phase (sertraline use)   
depression (bupropione initiation) 05 / 2005 9.2 
depression (trazodon initiation) 06 / 2005  
 08 / 2005 8.5 
improvement (trazodon dose increase) 09 / 2005  
further improvement 10 / 2005  
anxiety, diarrhea (sulpirid initiation) 11 / 2005  
 03 / 2006 8.1 
without problems 04 / 2006  
 05 / 2006 8.7 
 12 / 2006 8.2 
 06 / 2007 8.7 
 09 / 2007 8.2 
without problems 10 / 2007  
depression (sulpiride + sertraline) 12 / 2007  
without problems 01 / 2008 8.3 
 04 / 2008 7.6 
 07 / 2008 8.3 
memory deterioration (ginkgo initiation) 09 / 2008 7.8 
 04 / 2009 8.6 
 06 / 2009 8.5 
 09 / 2009 8.9 
 03 / 2010 8.5 
without problems (sulpiride + sertraline) 05 / 2010  
 07 / 2010 8.1 
cooperation continuation 10 / 2010 8.5 
Table 3. Timeline of mental state and glycosylated hemoglobin level development - patient No.2 
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At a visit in October 2010, she agreed on a gradual withdrawal of the nootropic agent.  
CGI-S – 1 point. She requested chronic use of the other treatment. At present, the patient 
comes for psychiatric visits every six months and feels mentally stabilized despite lasting 
somatic problems. 
Her glycemic control at the first psychiatric visit (i.e. May 2005) was 9.1% HbA1c. The value 
decreased to 8.4% in August same year, and 8.0% in March 2006. The value was higher 
again (8.7%) in May 2006. The glycosylated hemoglobin decreased to 8.1% again in 
December 2006. It was 8.7% in June 2007, 8.1% in September 2007, 8.2% in January 2008, 
7.6% in April, 8.2% in July, and 7.8% in September. The value was 8.6% in April 2009, 8.4% 
in June, and 8.9% in September. The glycosylated hemoglobin was 8.4% in March 2010, and 
8.0% in July. The glycosylated hemoglobin was 8.4% at the last blood examination in 
October 2010. 
Body weight of the patient was 79 kg at the beginning of the treatment (May 2005), 80 kg 
after 3 months, than it decreased to 72 kg and stayed until May 2006. It increased to 77 kg in 
September 2006 and 80 kg in April 2009. It was 82 kg in the end of the follow-up in February 
2011. The body weight of the patient thus decreased at the beginning of the treatment, it 
returned to its original value after 4 years and subsequently kept gradually increasing. 
Blood pressure of the patient hovered around 120/60 torr during the whole treatment. It did 
not change due to antidepressant therapy. 
Her serum triglyceride level was 0.76 mmol/l at the beginning of the treatment and 0.59 
mmol/l in the end of the follow-up, it did not change owing to the psychiatric treatment. 
Serum cholesterol level was 5.58 mmol/l at the beginning of the treatment and 5.95 mmol/l 
in the end of the follow-up, there was no significant change due to the psychiatric treatment. 
Mental state of the patient improved, although very slowly, since the beginning of the 
treatment. It was necessary to change repeatedly her psychiatric drugs for insufficient effect 
and intermittent decompensations of her mental state. Even her glycemic control was 
slightly improving at the beginning, subsequently, a tendency of glycosylated hemoglobin 
to fluctuate was observed at times of varying mental state compensation as well as in long 
periods of mental stability. Her mental state, despite periods of subcompensation, is 
significantly improved after several years of psychiatric treatment than it was before 
treatment commencement. Glycosylated hemoglobin level is also lower than prior to 
treatment despite its fluctuations. It did not return to the original high value. 
This case demonstrates the influence of fluctuating mental compensation on fluctuation in 
long-term glycemic control, although it is not possible to observe a direct temporal 
relationship. It is acknowledged that a change in glycosylated hemoglobin always occurs 
with a delay after a change in condition of a patient, i.e. treatment change, attitude towards 
treatment change, better self-monitoring, etc. The delay duration ranges usually in weeks. 
No exact correlation of individual changes in time can be observed in the relationship of 
mental compensation and glycemic control.  
Patient No. 3 was born in 1966. She was diagnosed with diabetes mellitus in 1989, i.e. in her 
23 years. Regarding organ complications of diabetes she suffers from diabetic nephropathy 
and retinopathy. She was also diagnosed with pulmonary fibrosis,  she went through a lung 
biopsy in 1989. Her condition is stable with no functional impairment. She has been treated 
www.intechopen.com
Antidepressant Drug Use in Patients with Diabetes Mellitus Type 1 –  
The Effect of Medication on Mental Problems and Glycemic Control 173 
for iron deficiency anemia since 1995. Her grandfather had a diabetes mellitus type II. 
Regarding psychiatric family history, her sister had collapse states and epilepsia in her 
childhood and her father suffers from dementia. The patient is married and has three 
children. She was just after maternity leave at time of psychiatric treatment. She did not 
work, she took care after her ill father. She was employed as a secretary in past. She was 
content in her partner life, but she was overburdened by care of her father and had conflicts 
with her mother-in-law.  
She herself requested psychiatric care for feelings of  anxiety/depression and painful 
diabetic polyneuropathy in May 2005, i.e. in her 39 years. She reported progressing feelings 
of anxiety, fear of closed-in places and tight clothing, tearfulness, sleeping disorder, 
hypobulia, constipation and headache for about one and a half year on the first examination. 
She felt overburdened, hurried and tired. She was losing her sexual appetite. 
A psychomotor retardation, depressive mood, apathy, hypobulia and labile emotionality 
was evident in contact. The patient was significantly influenced by an apparent inner 
tension. CGI-S – 5 points. 
A diagnosis of anxious depressive disorder was made and sertraline treatment at a daily 
dose of 100mg with a gradual titration from 50mg per day was started (May 2005). 
At a visit the following month (June 2005) the patient reported an alleviation from anxiety. 
She was less agitated and more satisfied, she did not get disturbed so easily, but her anxiety 
prevailed in stress situations. The headache disappeared almost completely. CGI-S – 2 
points. She was in an even better condition in July 2005; even sleeping and sexual appetite 
normalized. She was able to manage better her stress situations and was able to look for 
their solutions in more tranquility. In September, she complained about a slight 
deterioration of anxiety as a reaction to a stress at home, she was tearful and subdepressive. 
CGI-S – 3 points. Sertraline dose was therefore increased to 150mg per day. Consequently, 
her mental state stabilized again.  
In January 2006, the patient complained about gastric problems that lasted for about a week 
and came always after sertraline ingestion. The problems comprised of a stomachache, 
nausea and even vomiting. From the psychiatric point of view, her mental stability 
prevailed, anxious states came occasionally and she was able to solve them easily. 
Withdrawal of the psychiatric medication was impossible owing to the short duration of 
mental state stabilization. Sulpirid at a daily dose of 50mg was added because of tendencies 
of the patient to somatize her problems. 
Then in February, the patient complained about deterioration of her problems with vertigo, 
which she had had before, but had never spoken about. Meanwhile, her diabetologist 
changed the medication to 25mg of amitriptyline per day. After all examinations performed 
during hospitalization to find the origin of the vertigo, it was found to be psychogenic. The 
change in medication caused a mental decompensation of the patient, the symptoms of 
anxiety, tearfulness and inability to solve common problems returned, the headache  came 
back. Moreover, she was terrified by her mental state deterioration, it was completely 
unexpected for her and she lost confidence in the medication. CGI-S – 4 points. Amitriptiline 
was continued and the dose was increased to 50mg per day. The patient was educated in 
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detail regarding the action of the medication and encouraged to endure until onset of 
antipsychotic medication effects. She felt already well at a visit next month, in March 2006; 
she was without depression and headache, the vertigo attenuated. CGI-S – 2 points. In 
May, she was without depression and sleeping disorder, however the headache worsened 
slightly and occasionally she had an episode of anxiety, which was difficult to manage. 
Sometimes she was more easily distressed. CGI-S – 3 points. The dose of amitriptiline was 
thus increased to 75mg per day. In July 2006, the mental state of the patient was well 
compensated, she was without depression, sleeping disorder and headache, occasional 
anxiety was well tolerated. CGI-S – 2 points. The patient was satisfied and asked for 
termination of psychiatric consultations. She wished to continue the medication under a 
supervision of her diabetologist. She promised she would come for a psychiatric visit in 
case of mental state deterioration or for treatment withdrawal after about one year. In the 
end, amitriptiline was discontinued by her diabetologist in January 2008, because of 
fatigability and insufficient effect on pain in lower extremities from diabetic painful 
polyneuropathy. 
Glycosylated hemoglobin was 14.6% prior to psychiatric treatment commencement in May 
2005. It was 14.1% in June, 12.4% in November. It was 10.3% in February 2006, 11.4% in 
May, 10.8% in August and 10.9% in December 2006. Glycosylated hemoglobin was 9.7% in 
March 2007, 10.5% in June, and 14.3% again in October 2007.    
 
Psychological status (treatment) Time HbA1c CGI-S 
anxiety depression problems (sertraline treatment initation) 05 / 2005 14.6 5 
anxiety only in stress 06 / 2005 14.1 2 
Improvement 07 / 2005  2 
anxiety improvement, sebdepression (sertraline dose increase) 09 / 2005  3 
without problems 11 / 2005 12.4 3 
gastric problems (sulpiride initiation) 01 / 2006  3 
vertigo (amitriptyline initiation), deterioration 02 / 2006 10.3 4 
Improvement 03 / 2006  2 
deterioration (amitriptyline dose increase) 05 / 2006 11.4 3 
without problems, cooperation termination 07 / 2006  2 
 08 / 2006 10.8 2 
 12 / 2006 10.9  
 03 / 2007 9.7  
 06 / 2007 10.5  
 10 / 2007 14.3  
medication withdrawal 01 / 2008   
Table 4. Timeline of mental state and glycosylated hemoglobin level development - patient No.3 
Body weight of the patient was 78 kg at the beginning of the treatment (May 2005), it was 
gradually increasing to 80 kg during the year, in the course of the next year it was 
decreasing to 74 kg in the end of the year (January 2010). 
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Blood pressure of the patient ranged from 120/70 to 130/70 torr during the whole course of 
the treatment. It did not change owing to the antidepressant drug treatment.  
The serum triglycerides level was 1.66 mmol/l at the beginning of the treatment, 2.2 mmol/l 
in the end, there was therefore a mild increase observed. Serum cholesterol was 5.68 mmol/l 
at the beginning of the treatment and 5.84 mmol/l in the end, the increase due to psychiatric 
treatment was thus only insignificant. 
Mental state of the patient slowly improved, it was necessary to change medication because 
of insufficient effect, but also due to the fact that the patient reported only a part of her 
problems, negated the rest and these emerged later as chronic problems. Later, the patient 
refused to attend psychiatric out-patient clinic. She explained it by good stability of her 
state. She wanted to be followed only by her diabetologist, where the 
psychopharmacological treatment continued for another year and a half and was then 
withdrawn. The mental state in a long-term is not stable, neither on medication, nor after its 
withdrawal, however, she did not come back to psychiatrist's care. Her glycemic control 
improved significantly at the beginning of the treatment, however, it returned to its original 
value after the antidepressant withdrawal. 
In this case the effect of supportive counseling was quite substantial, although it was not the 
case of systemic psychotherapy. The patient was in a difficult life situation and apart of 
medication she was receiving the support she needed. It can also be seen here, that the 
patient did not have the insight into her mental problems, it was necessary to keep asking 
about them repeatedly. 
Patient no. 4 was born in 1970 and suffers from diabetes mellitus type 1 since 1996, i.e. since 
his 26 years. He did not have any organ complications diagnosed at time of psychiatric 
treatment. He is also treated for arterial hypertension and hypercholesterolemia. There was 
no family history of diabetes nor mental disorder. The patient works a clerk, is single, 
childless, lives alone.  
He has been in psychiatric care since December 2005, i.e. since he was 35 years old. He was 
referred by his diabetologist for about 2 years of incompliance in diabetes treatment, active 
refusal of maintaining the daily regimen and hospitalization for treatment correction. The 
diabetologist referred him to psychiatry for a suspicion of a mental illness.  
The patient admitted a deterioration of his mental state lasting for about 2 years on 
examination. He is afraid of a large number of people, gets easily distressed, is emotionally 
labile, has depressive moods with feelings of hopelessness that come unreasonably. He has 
his insight into the fact that he lacks the motivation for diabetes treatment. This condition 
lasts for about 2 years already. He used to cope with his disease well before. At present he 
has conflicts with the doctors at the department of Diabetology.  
In contact he was tense, anxious, with labile emotionality, depression, even resonant mood, 
apathetic. CGI-S – 5 points. 
A diagnosis of anxiety depression disorder was made and a sertraline treatment at a dose 
gradually up to 100mg per day was initiated. At a visit two weeks after, the patient felt 
better, he was subdepressed, less anxious, but he complained that he was not motivated by 
any life goal; he lives from one day to another, is indifferent. CGI-S – 3 points. He felt 
significantly better in January 2006, he reported better cooperation with doctors at the 
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department of Diabetology. He was getting insight into his share in the conflicts. CGI-S – 2 
points.  The mental state of the patient was completely restituted in February, he felt happy, 
he perceived occasional fluctuation of his mood as natural, he reported significant 
improvement in his glycemic control. He was very satisfied with the improvement and it 
motivated him to further improve the cooperation. Again, he found meaning in good 
treatment and control of his basic disease. CGI-S – 1 point. At a visit in August 2008, he 
reported that apart from further improvement he is successful in losing weight - he gained a 
few kilograms in previous two years. After mutual agreement, the patient was referred to 
diabetology out-patient clinic with set medication. He should come for a psychiatric check 
up if needed. He did not come and spontaneously discontinued the medication in the end of 
2007, supposedly for financial reasons. 
His long-term glycemic control at the beginning of the treatment was very unsatisfactory, 
the glycosylated hemoglobin level was 10.7% in January 2006, it  decreased to 9.3% already 
in March, 9.6% in June, 9.9% in October. In January 2007 the level was 10.1%, followed by 
9.9% in April, 9.6% in August, 10.1% in November, and finally 10.8% in March 2008.  
 
Psychological status (treatment) Time HbA1c CGI-S 
anxiety depression problems (sertraline treatment) initation 12 / 2005  5 
Improvement 01 / 2006 10.7 2 
full compansation 02 / 2006  1 
 03 / 2006 9.3 1 
 06 / 2006 9.6 1 
compliance improvement 08 / 2006  1 
cooperation termination 10 / 2006 9.9  
continuation in medication 01 / 2007 10.1  
 04 / 2007 9.9  
 08 / 2007 9.6  
 11 / 2007 10.1  
medication withdrawal 12 / 2007   
 03 / 2008 10.8  
Table 5. Timeline of mental state and glycosylated hemoglobin level development - patient No.4 
Body weight of the patient was 97 kg at the beginning of the treatment (December 2005), it 
was 93 kg in the end (March 2008). A weight loss 4 kg was thus observed in the course of the 
treatment.  
Blood pressure of the patient ranged from 140/80 torr at the beginning of the treatment to 
130/70 torr in its end. It thus mildly decreased owing to the antidepressant drug therapy in 
the course of the treatment. 
Serum triglyceride level was 1.28 mmol/l at the beginning of the treatment, 1.23 mmol/ in 
the end, it did not change due to the psychiatric therapy. Serum cholesterol level was 4.56 
mmol/l at the beginning of the treatment, it decreased significantly to 3.58 mmol/l after 3 
months and then mildly increased again up to 5.1 mmol/l in the end of the treatment.  
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The mental state of the patient improved quite rapidly and a significantly better cooperation 
in maintaining diabetic regimen was associated with it. Glycosylated hemoglobin at the 
beginning of the treatment decreased significantly, however, after the antidepressant 
medication withdrawal it returned to its original value prior to the treatment. 
This case demonstrates that a mental disorder can induce incompliance of a patient and 
poor glycemic control. It is also evident here that the mental state deteriorated after the 
termination of the cooperation with a psychiatrist, or psychotherapy withdrawal. 
3. Discussion  
To our knowledge, there has not been found another scientific work that would deal with 
mechanisms of the effect of antidepressant drugs on glycemic control. The effect of mental 
state improvement using antidepressants is doubtless. It leads to attenuation of chronic 
stress and improvement in compliance with the diabetes treatment. Biochemical context is 
surely also in play. More research needs to be done in this field.  
The medication of choice in all patients was sertraline for its efficacy against a wide 
spectrum of anxiety-depression symptoms. We often choose it for its safety regarding 
adverse effects and drug interactions. The individual patients were subsequently treated by 
various antidepressant drugs as individualized care was emphasized. The medication was 
thus selected according to specific problems and history of patients. Patients with varied 
initial glycemic control and a different change in glycemic control in course of the treatment 
and after the treatment termination are deliberately described here in order to be able to 
show multiple aspects of antidepressant drug effect in diabetic patients with a mental 
disorder. This variability was also chosen in order to enable demonstration of several 
possible pitfalls in treatment of these patients. 
In spite of the fact that evaluation of the effect of individual groups of antidepressants in 
diabetic patients was not an objective of this work, it is suitable to share some experience 
from our psychiatric out-patient department. Drugs of choice are antidepressant drugs from 
the group of SSRI, especially aforementioned sertraline, for their effectiveness in the 
treatment of anxiety and depression problems, low risk of drug interactions and a small 
influence on body weight of patients. A potential contribution of SSRI to blood glucose 
decrease can also be beneficial in these patients. [Češková, 2004] Another commonly used 
drug is trazodone (SARI) for its good hypnotic and anxiolytic effect as well as the fact that it 
has no influence on body weight and sexual appetence. Venlafaxine (SNRI) is also 
frequently used for its good therapeutic effect on anxiety and depression symptoms and 
minimal metabolic adverse effects. Duloxetine from the same group of antidepressants is 
used for its effect on neuropathic pain alleviation. Unfortunately, it is not available to 
psychiatrists in the Czech Republic, only to neurologists. Tricyclic antidepressants, 
especially amitriptiline, are used mainly in the patients with painful diabetic neuropathy 
and associated sleep disorders. However, a frequent appetite and body weight increase limit 
their use. Antidepressants from the MAOI group (moclobemide) are scarcely used for their 
unconvincing clinical antidepressant effectiveness although they do not have any negative 
metabolic adverse effects. Bupropion (NDRI) has a good effect on inhibitedness and does 
not influence body weight, nonetheless, quite common and considerable increase in tension 
and anxiety constitute limiting adverse effects for its use. Mirtazapine (NaSSA) is an 
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unsuitable drug for diabetic patients for augmented appetite, weight gain and glycosylated 
hemoglobin level increase. [Šabaková, 2008] 
Other somatic and metabolic parameters, which could have been influenced by the 
treatment, were monitored in the course of treatment of all abovementioned patients. 
[Svačina, 2004] The most significant change in monitored parameters was in the 
measurements of body weight of the patients, although the change was completely 
inconsistent. In the first patient, the body weight gradually increased. In the second one, it 
decreased at first, then returned to its original value. In the next patient, it slowly increased 
at first and then decreased significantly. In the last patient, the body weight significantly 
decreased during the whole course of the psychiatric treatment. The blood pressure values 
remained basically unchanged, as well as their blood cholesterol level. Only the serum 
triglyceride level increased in two patients in the course of the treatment, however, it was 
not possible to prove a direct association with antidepressant drug treatment here.  
The focus of this work on antidepressant drugs does not allow broader addressing of issues 
concerning the origin of the mental problems, e.g. the influence of diabetes as a chronic 
disease, life crisis, etc. [Rossová, 1992] Even these factors undoubtedly significantly 
influence the treatment using antidepressant drugs and their effect on glycemic control. 
Another important factor in this context is premorbid personality structure. It is acknowledged 
that antidepressant drug treatment of mental state decompensation is controversial in personal 
psychopatology. It could thus also have a smaller effect on glycemic control. 
The psychiatric care cannot be perceived merely as the effect of psychotropic drugs. The 
counseling with a doctor have a certain psychotherapeutic potential, although it is not a form 
of systemic psychotherapy. A certain part of the session is psychoeducation and motivational 
and supportive interview. [Beran, 2000] Even this aspect needs to be taken in account when we 
evaluate the effect of antidepressants on a glycemic control in patients in psychiatric care. 
Some patients with the described problems can profit from antidepressant medication, some 
from the systemic psychotherapy, some from the combination of the two. The indication of 
both should be wise. The antidepressant drugs are especially important in patients with a 
somatic disease as is diabetes mellitus, as these patients require quite lengthy 
psychotherapeutic work because of their significant orientation on somatic problems and 
laboratory findings. The need for mental state improvement, cooperation and glycemic 
control is often urgent. The treatment is thus often started with antidepressants and the 
psychotherapy is added after at least a partial improvement of the mental state.  
Another issue is the eventual withdrawal of the medication. This is commonly dictated by 
the same rules as in other patients with mental illness. For some patients a long-term 
medication is beneficial, in spite of the fact that their mental problems long have 
disappeared. However, it was demonstrated that the patients should be left in the care of a 
psychiatrist during the whole time of medication administration. 
Also, when initiating psychotherapeutic medication, all patients should be examined and 
educated by a psychiatrist. It is beneficial when the treatment can be indicated by a 
diabetologist to enable a fast treatment initiation, however, it has been proven that even 
psychoeducation and education regarding treatment is a very important part of a successful 
therapy and should therefore be performed by a professional. The advantage of a 
psychiatrist is also the ability to choose from a broader spectrum of psychiatric drugs.  
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4. Conclusion  
The case studies demonstrate that the effect of an antidepressant drug on glycemic control 
improvement in patients with comorbid psychiatric disorder is possible.  
Mental state of diabetic patients when treated by antidepressant drugs changes similarly as 
in the rest of the population, i.e. rapidly in some, slowly in others, and in some a change in 
medication is needed. The glycemic control improvement is associated especially with the 
mental state improvement. In most patients the improvement in glycemic control was 
evident at the beginning of the treatment. The fact that the diabetic patient is introduced 
with a completely new treatment modality of his disease, i.e. psychiatric treatment, plays a 
positive role. The patients with a lasting improvement in their mental state have a high 
probability of persisting improved glycemic control. The deterioration of the basic disease 
can be expected in the diabetic patients, who mentally deteriorate  some time after the 
antidepressant treatment withdrawal. 
It is necessary to treat mental disorders in diabetic patients, as the antidepressant drug 
treatment has a positive effect not only on their mental state, which is associated with their 
compliance, but also it can positively influence the glycemic control, which is desirable even if 
the improvement were only temporary. Correctly selected antidepressants should not have an 
adverse effect on other somatic and metabolic parameters. Mental problems of diabetic 
patients should be treated by a psychiatrist educated in the problems of diabetes, because 
psychoeducation and a support of the patient are appropriate parts of the treatment.  
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